Checks how CFTR modulator medicines work in people with cystic fibrosis
Observes how CFTR modulator medicines affect CFTR function in people with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
Key facts
- Where
- Berlin, Giessen, Hanover, and Heidelberg, GermanySee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cystic fibrosis who have decided, together with their CF doctor, to start CFTR-modulator therapy. It observes how the therapy affects CFTR function.
- Age
- From 6 months of age. No upper age limit is given.
- Sex
- All sexes can join.
Main reasons for not taking part
- Currently taking part in a study of an investigational drug, including studies of lumacaftor, tezacaftor or ivacaftor
Read by machine on 9 November 2026.
Where in Germany
- Charité Universitätsmedizin BerlinBerlin, GermanyTaking people
- Justus Liebig University GiessenGiessen, GermanyTaking people
- Hannover Medical SchoolHanover, GermanyTaking people
- University of HeidelbergHeidelberg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Charite University, Berlin, Germany
- Trial code
- NCT04732910
- Record updated
- 24 February 2026
- Original description
This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).Read full original descriptionShow less
CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie
This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).
Inclusion: Decision for cystic fibrosis (CF) transmembrane regulator (CFTR)-modulator therapy by the patient and the caring CF physician; Signed informed consent form (ICF) and, where appropriate, signed assent form.
Exclusion: Ongoing participation in an investigational drug study (including studies investigating lumacaftor, tezacaftor or ivacaftor).